Nonalcoholic Fatty Liver Disease
Conditions
Interventions
Spleen and kidney deficiency:QHF+Codonopsis, Chinese yam, Astragalus, Cinnamon+diet and exercise based treatment
Liver stagnation and spleen deficiency :QHF+Angelica, Paeony, Bupleurum+diet and exercise based treatment
Damp heat accumulation:QHF+Bamboo leaves, Magnolia officinalis, Coix seed,oriental wormwood+diet and exercise based treatment
damp turbidity :QHF+diet and exercise based treatment
Control Group :diet and exercise based treatment
Phlegm and blood stasis :QHF+Peach kernel, peony root,radix curcumae+diet and exercise based treatment
Sponsors
Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age 18 to 75 years; 2.Patients who meet the above western medical diagnostic criteria and the wet turbidity internal stop certificate; 3.Patients who are willing to sign informed consent. 4.Serum alanine aminotransferase (ALT) = 2 times the upper limit of normal, total bilirubin (TBIL) = 2 times the upper limit of normal
Exclusion criteria
Exclusion criteria: 1. Patients with fatty liver, Reye syndrome fatty liver, ß-lipoprotein deficiency and localized fatty liver caused by chronic heart failure, malnutrition and pregnancy. Patients with fatty liver caused by diabetes, long-term use of hormones, small intestinal bypass surgery, toxic injury to liver cells, chronic febrile diseases such as tuberculosis, ulcerative colitis, and chronic infection after gastrointestinal surgery. 2. Severe fatty liver with ascites, edema, hyponatremia, hypokalemia and other suspected manifestations of liver cirrhosis; hepatitis or cirrhosis caused by virus, drug poisoning, immune diseases and other factors. 3. Other Chinese and Western medicines for the treatment of simple fatty liver have been used after this onset. 4. Patients who have serious primary cardiovascular disease, liver disease, kidney disease, hematological disease, lung disease, or serious diseases that affect their survival, such as tumor or AIDS. 5. Mentally or legally disabled patients. 6. Suspected or indeed have a history of alcohol or drug abuse, or other diseases that reduce the possibility of enrollment or complicate enrollment according to the judgment of the investigator, such as frequent changes in the working environment, which are likely to cause loss to follow-up. 7. Those who are known to be allergic to the components of this medicine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The liver ultrasound;Fibroscan; | — |
Secondary
| Measure | Time frame |
|---|---|
| HOMA-IR;Serum biochemistry;WHR;InISI;BMI;curative effect; | — |
Countries
China
Contacts
Public ContactLiYing
Outcome results
None listed